Partha Basu, Anuradha Talukdar, Poulome Mukherjee, Richard Muwonge, Eric Lucas, Monoj Kumar Deka, Amanjit Bal, Upasana Gautam, Manish Rohilla, Baneet Bansal, Veenu Singla, Siddhant Khare, Andre Lopes Carvalho, Anita Gadgil, Ravi Kannan, Radhika Srinivasan
{"title":"Automated mRNA-Based Detection of ER, PR, HER2, and Ki-67 in Breast Cancer Tissue and Cytology Samples in Resource-Limited Settings.","authors":"Partha Basu, Anuradha Talukdar, Poulome Mukherjee, Richard Muwonge, Eric Lucas, Monoj Kumar Deka, Amanjit Bal, Upasana Gautam, Manish Rohilla, Baneet Bansal, Veenu Singla, Siddhant Khare, Andre Lopes Carvalho, Anita Gadgil, Ravi Kannan, Radhika Srinivasan","doi":"10.1002/cam4.72359","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Accurate detection of estrogen and progesterone receptors (ER/PR), HER2, and Ki-67 is essential for molecular classification of breast cancer and in deciding upon tailored treatment. In many low- and middle-income countries (LMICs), access to histopathology and immunohistochemistry (IHC) is limited. STRAT4, an automated RT-qPCR assay performed on the widely available GeneXpert platform, offers a potential alternative. We evaluated the performance of STRAT4 on core biopsy, unstained smear of fine-needle aspiration biopsy (FNAB-US), and cellblock samples compared with conventional IHC in 178 histopathology-confirmed breast cancer patients.</p><p><strong>Methods: </strong>Matched core biopsy, cellblock, and FNAB-US samples were analyzed using STRAT4. Concordance with IHC for ER, PR, HER2, and Ki-67 was assessed using percentage agreement and kappa statistics. The effect of alternative dC<sub>t</sub> cut-offs used in an earlier study was also examined. Molecular subtype classification derived from STRAT4 was compared with IHC-based classification.</p><p><strong>Results: </strong>Concordance between STRAT4 and IHC was high for ER across all sample types (κ: 0.78-0.86). PR detection showed substantial agreement for core biopsies (κ = 0.78) and cellblocks (κ = 0.63), but only fair for FNAB-US samples (κ = 0.53). HER2 detection showed moderate agreement (κ = 0.41-0.58), improving with modified cut-offs (κ = 0.57-0.66), especially for FNAB-US. Ki-67 concordance was low (agreement 58.9%-71.0%). Kappa values indicating agreement between molecular subtype classifications using STRAT4 on various samples and routine IHC were as follows: core biopsies = 0.60; cellblocks = 0.61; FNAB-US samples = 0.45.</p><p><strong>Conclusion: </strong>Detection of ER from FNAB-US, cellblocks, and core biopsies using STRAT4 showed high concordance with IHC. However, the concordance was low to moderate for other markers.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":"e72359"},"PeriodicalIF":3.5000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639388/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cam4.72359","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Accurate detection of estrogen and progesterone receptors (ER/PR), HER2, and Ki-67 is essential for molecular classification of breast cancer and in deciding upon tailored treatment. In many low- and middle-income countries (LMICs), access to histopathology and immunohistochemistry (IHC) is limited. STRAT4, an automated RT-qPCR assay performed on the widely available GeneXpert platform, offers a potential alternative. We evaluated the performance of STRAT4 on core biopsy, unstained smear of fine-needle aspiration biopsy (FNAB-US), and cellblock samples compared with conventional IHC in 178 histopathology-confirmed breast cancer patients.
Methods: Matched core biopsy, cellblock, and FNAB-US samples were analyzed using STRAT4. Concordance with IHC for ER, PR, HER2, and Ki-67 was assessed using percentage agreement and kappa statistics. The effect of alternative dCt cut-offs used in an earlier study was also examined. Molecular subtype classification derived from STRAT4 was compared with IHC-based classification.
Results: Concordance between STRAT4 and IHC was high for ER across all sample types (κ: 0.78-0.86). PR detection showed substantial agreement for core biopsies (κ = 0.78) and cellblocks (κ = 0.63), but only fair for FNAB-US samples (κ = 0.53). HER2 detection showed moderate agreement (κ = 0.41-0.58), improving with modified cut-offs (κ = 0.57-0.66), especially for FNAB-US. Ki-67 concordance was low (agreement 58.9%-71.0%). Kappa values indicating agreement between molecular subtype classifications using STRAT4 on various samples and routine IHC were as follows: core biopsies = 0.60; cellblocks = 0.61; FNAB-US samples = 0.45.
Conclusion: Detection of ER from FNAB-US, cellblocks, and core biopsies using STRAT4 showed high concordance with IHC. However, the concordance was low to moderate for other markers.
期刊介绍:
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.